Antimicrobial Development in the Era of Emerging Resistance

作者：Sorlozano Antonio; Carrasco Cristina; Cabeza Jose; Villegas Enrique; Gutierrez Jose^*

来源：Mini Reviews in Medicinal Chemistry, 2009, 9(8): 938-955.

DOI：10.2174/138955709788681564

• Faropenem
• dalbavancin
• telavancin
• oritavancin
• ceftobiprole
• iclaprim

Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.

• 出版日期2009-7